NASDAQ:NTLA

Intellia Therapeutics Stock News

Healthcare > Biotechnology

Buy NTLA

*Your capital is at risk

$13.02

-1.20 (-8.41%)

At Close: Jul 13, 2026

FDA Accepts Investigational New Drug Application for CRISPR/Cas9-Based Sickle Cell Disease Therapeutic Candidate Developed Under Collaboration with Intellia Therapeutics

11:30am, Tuesday, 31'st Mar 2020

Intellia Therapeutics, Inc. (NTLA), a leading genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology both in vivo and ex vivo, announced that the U.S. Food

Top Fintech Company

featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by